MedPath

Pemetrexed

Generic Name
Pemetrexed
Brand Names
Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
Drug Type
Small Molecule
Chemical Formula
C20H21N5O6
CAS Number
137281-23-3
Unique Ingredient Identifier
04Q9AIZ7NO
Background

Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication

Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions
Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
Associated Therapies
Monotherapy
Clinical Trials
Related News

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Phase 3
Not yet recruiting
Conditions
Advanced and Metastatic NSCLC
Interventions
First Posted Date
2024-11-26
Last Posted Date
2024-12-16
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
430
Registration Number
NCT06704620
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1
Not yet recruiting
Conditions
Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small Cell Lung
Non-Small Cell Lung Carcinoma
Non Small Cell Lung Cancer
Non Small Cell Lung Carcinoma
Interventions
First Posted Date
2024-11-19
Last Posted Date
2025-05-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT06694454
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

Phase 2
Not yet recruiting
Conditions
Lung Cancer
Interventions
First Posted Date
2024-11-14
Last Posted Date
2024-11-14
Lead Sponsor
Shanghai Chest Hospital
Target Recruit Count
30
Registration Number
NCT06688656
Locations
🇨🇳

241, West Huaihai Road, Shanghai, Shanghai, Shanghai, China

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Phase 3
Recruiting
Conditions
Non Squamous Non Small Cell Lung Cancer
Interventions
Drug: EU-sourced Keytruda®
Drug: US-sourced Keytruda®
First Posted Date
2024-11-13
Last Posted Date
2025-05-21
Lead Sponsor
mAbxience Research S.L.
Target Recruit Count
726
Registration Number
NCT06687369
Locations
🇬🇪

Site 108002, Tbilisi, Georgia

🇷🇸

Site 121005, Užice, Serbia

🇯🇵

Site 207002, Hakodate-shi, Japan

and more 13 locations

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2
Recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
First Posted Date
2024-10-31
Last Posted Date
2025-05-04
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
365
Registration Number
NCT06667076
Locations
🇺🇸

Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States

🇺🇸

Investigative Clinical Research of Indiana, LLC, Noblesville, Indiana, United States

🇺🇸

Accellacare of McFarland, Ames, Iowa, United States

and more 87 locations

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Phase 1
Recruiting
Conditions
Lung Cancer (NSCLC)
Leptomeningeal Metastasis
Interventions
First Posted Date
2024-10-29
Last Posted Date
2024-10-29
Lead Sponsor
Shanghai Chest Hospital
Target Recruit Count
19
Registration Number
NCT06663306
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, China

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Phase 2
Recruiting
Conditions
Lung Cancer, Non-Small Cell
Interventions
First Posted Date
2024-10-26
Last Posted Date
2025-05-18
Lead Sponsor
Shanghai Chest Hospital
Target Recruit Count
32
Registration Number
NCT06659042
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3
Recruiting
Conditions
Resectable Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Interventions
Procedure: Surgical Procedure
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
First Posted Date
2024-10-09
Last Posted Date
2025-03-30
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
1100
Registration Number
NCT06632327
Locations
🇺🇸

South Sacramento Cancer Center, Sacramento, California, United States

🇺🇸

Kaiser Permanente-San Francisco, San Francisco, California, United States

🇺🇸

Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States

and more 223 locations

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients with Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2
Not yet recruiting
Conditions
Advanced Breast Carcinoma
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Advanced Pancreatic Carcinoma
Advanced Prostate Carcinoma
Advanced Sarcoma
Anatomic Stage III Breast Cancer AJCC V8
Anatomic Stage IV Breast Cancer AJCC V8
Stage III Ovarian Cancer AJCC V8
Stage III Pancreatic Cancer AJCC V8
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Other: Survey Administration
First Posted Date
2024-10-08
Last Posted Date
2025-02-13
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
30
Registration Number
NCT06630325
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Phase 2
Recruiting
Conditions
Metastatic Bladder Urothelial Carcinoma
Metastatic Malignant Solid Neoplasm
Stage IV Bladder Cancer AJCC v8
Interventions
Procedure: Biospecimen Collection
Procedure: Computed Tomography
First Posted Date
2024-10-08
Last Posted Date
2024-12-02
Lead Sponsor
Northwestern University
Target Recruit Count
64
Registration Number
NCT06630416
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy